Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Equivalents (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Cash & Equivalents for 16 consecutive years, with $267625.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 62.76% year-over-year to $267625.0, compared with a TTM value of $267625.0 through Sep 2025, down 62.76%, and an annual FY2024 reading of $626879.0, down 55.97% over the prior year.
  • Cash & Equivalents was $267625.0 for Q3 2025 at China Pharma Holdings, down from $625032.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $4.9 million in Q4 2021 and bottomed at $267625.0 in Q3 2025.
  • Average Cash & Equivalents over 5 years is $1.4 million, with a median of $901910.0 recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 594.97% in 2022, then crashed 68.59% in 2023.
  • Year by year, Cash & Equivalents stood at $4.9 million in 2021, then tumbled by 58.22% to $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plummeted by 55.97% to $626879.0 in 2024, then plummeted by 57.31% to $267625.0 in 2025.
  • Business Quant data shows Cash & Equivalents for CPHI at $267625.0 in Q3 2025, $625032.0 in Q2 2025, and $412688.0 in Q1 2025.